Trial · NCT02812342
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
NCT02812342, Phase 2, Completed, Yale University; results first posted 2018-10-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants. Trials, record NCT02812342. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02812342
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
- NCT number
- NCT02812342
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Interventions
- Tofacitinib ointment
- First posted
- 2016-06-24
- Last updated
- 2019-01-30
- Results first posted
- 2018-10-10
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Severity of Alopecia Tool (SALT) Score | 6 Months | SALT score range is from 0 (no hair loss) to 100 (100% hair loss). A positive percent change from baseline corresponds to a reduction in SALT score, and in this study study will be measured between baseline and 6 months. |
| Secondary | Treatment Response Assessed as the Number of Participants With Hair Regrowth | 6 Months | Clinical photographs will be used to demonstrate presence or absence of hair regrowth. Presented is a count of people that did respond to treatment. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Severity of Alopecia Tool (SALT) Score | 6 Months | percent change | MEAN | |
| SECONDARY | Treatment Response Assessed as the Number of Participants With Hair Regrowth | 6 Months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Severity of Alopecia Tool (SALT) Score | Tofacitinib Ointment | 10 | Full Range 0 to 61 | percent change | |
| Treatment Response Assessed as the Number of Participants With Hair Regrowth | Tofacitinib Ointment | 3 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tofacitinib Ointment | 10 | |
| Overall Study | COMPLETED | Tofacitinib Ointment | 10 | |
| Overall Study | NOT COMPLETED | Tofacitinib Ointment | 0 |
Source ClinicalTrials.gov
Adverse events5
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper Respiratory Infection | Infections and infestations | Tofacitinib Ointment | 4 | 10 | |
| other | Sinus Infection | Infections and infestations | Tofacitinib Ointment | 1 | 10 | |
| other | Headache | General disorders | Tofacitinib Ointment | 2 | 10 | |
| other | Folliculitis | Skin and subcutaneous tissue disorders | Tofacitinib Ointment | 1 | 10 | |
| other | Scalp Skin Irritation | Skin and subcutaneous tissue disorders | Tofacitinib Ointment | 4 | 10 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tofacitinib Ointment | 0 | 10 |
| Total, other adverse events | Tofacitinib Ointment | 7 | 10 |
| Total, serious adverse events | Tofacitinib Ointment | 0 | 10 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28619556 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02812342
GET https://conductscience.org/api/trials/v1/NCT02812342/registered